Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6 ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial by next month and potential ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Inovio Pharmaceuticals Inc.-4.78% $75.45M ...

After hours: 7:59:53 p.m. EST ...